Jonathon DS Holt, PhD, DABT, is an experienced drug developer focused on pre-clinical development and early stage strategy. With a history of successful lead identification and IND filings, Dr. Holt has progressed multiple candidate compounds into clinical trials across his 10 years of experience in emerging and start-up pharmaceutical companies. Dr. Holt has developed compounds for Parkinson’s disease (PD), depression, psychosis, pain, HIV prevention, overactive bladder and cardiovascular reperfusion injury. He has most recently led an NINDS-funded program to standardize models of neuroprotection in PD and supported the development of an HIV prevention product for women in Africa (currently in Phase III efficacy studies).

As the inventor on the patent for the DAMA compounds currently under investigation, Dr. Holt provides a key depth of programmatic knowledge and pre-clinical/drug development expertise to the development of DAMA compounds for the treatment of PD symptoms and prevention of treatment-related dyskinesia.